Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
How has the gastric cancer market size evolved in recent years?
The market for gastric cancer has experienced a swift expansion in the recent past. The market size, which stands at $3.17 billion in 2024, is anticipated to rise to $3.65 billion by 2025 with a compound annual growth rate (CAGR) of 15.4%. The notable growth in the historic phase is a result of numerous factors including the surge in the aging population, improved awareness about healthcare, a rise in genetic mutations, amplifying prevalence of unhealthy lifestyles, and increasing knowledge about cancer.
What are the predictions for the gastric cancer market size in the coming years?
In the coming years, the gastric cancer market is anticipated to witness swift expansion. By 2029, the market is slated to reach a valuation of $6.43 billion, with a compound annual growth rate (CAGR) standing at 15.2%. Several factors such as, mounting obesity levels, expansion of government health initiatives, investment surge in the healthcare sector, growing appeal for oral medicines, and the increase in cancer treatment centers can be credited for the forecasted rise. Future trends that can be witnessed over this period encompass combination chemotherapy, product augmentation, surgery aided by robotics, targeted treatments, strategic alliances, and innovative diagnostic instruments.
Get your gastric cancer market report here!
https://www.thebusinessresearchcompany.com/report/gastric-cancer-global-market-report
What key factors are fueling the growth of the gastric cancer market?
Increases in obesity rates are predicted to fuel the expansion of the gastric cancer market in the future. Obesity is a health condition marked by an excessive accumulation of body fat, typically measured by a body mass index (BMI) higher than 30, and this can lead to various health issues. The rise in obesity rates is attributed to factors such as poor dietary habits, inactive lifestyles, environmental factors, and genetic vulnerability. Additional body fat, particularly around the abdomen, is related to a greater risk of gastric cancer because obesity provokes chronic inflammation and disrupts metabolic processes, both of which are connected to the onset of cancer, leading to increased demand for gastric cancer treatment. For example, in March 2024, the World Health Organization, a Switzerland-based international organization, reported that about 1 in 8 people worldwide were obese in 2022, with 2.5 billion adults over 18 being overweight, including 890 million individuals having obesity. Among adult population, 43% were overweight, and 16% were obese. On top of that, 37 million children below the age of 5 were overweight, and over 390 million children and teenagers between ages 5 to 19 were overweight, which includes 160 million who were obese. Therefore, the escalating obesity rates are pushing the growth of the gastric cancer market.
How is the global gastric cancer market divided into key segments?
The gastric cancer market covered in this report is segmented –
1) By Type: Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor, Other Types
2) By Diagnosis: Endoscopy, Biopsy, Imaging Tests, Exploratory Surgery, Other Diagnosis
3) By Treatment: Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Palliative Care, Other Treatments
4) By Distribution Channel: Hospital Pharmacies, Specialty And Retail Pharmacies, Other Distribution Channels
Subsegments:
1) By Adenocarcinoma: Intestinal Type Adenocarcinoma, Diffuse Type Adenocarcinoma, Mixed Type Adenocarcinoma
2) By Lymphoma: Primary Gastric Lymphoma, Secondary Gastric Lymphoma
3) By Gastrointestinal Stromal Tumor (GIST): Primary GIST, Metastatic GIST
4) By Carcinoid Tumor: Gastric Carcinoid Type 1, Gastric Carcinoid Type 2, Gastric Carcinoid Type 3
5) By Other Types: Small Cell Carcinoma, Squamous Cell Carcinoma, Mixed Tumors
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20797&type=smp
Who are the key firms paving the way for growth in the gastric cancer market?
Major companies operating in the gastric cancer market are F. Hoffmann La Roche Ltd., Merck And Co. Inc., AbbVie Inc., Sanofi S.A., Bristol Myers Squibb Company, Abbott Laboratories, Novartis AG, GlaxoSmithKline Plc, Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Ipsen Biopharmaceuticals Inc., Ono Pharmaceutical Co. Ltd., Samsung Biologics Co. Ltd., Celltrion Healthcare Co. Ltd., Biocon Limited, Hanmi Pharmaceuticals, Mylan N.V., Taiho Oncology Inc., Hikma Pharmaceuticals PLC, Taiho Pharmaceuticals Co. Ltd., AROG Pharmaceuticals Inc.
What emerging trends are influencing the growth of the gastric cancer market?
Major companies operating in the gastric cancer market are focusing on developing technologically advanced solutions, such as companion diagnostic assays, to help ensure personalized treatment. A companion diagnostic assay is a test used to identify patients who are most likely to benefit from a specific therapeutic treatment based on the presence of certain biomarkers. For instance, in October 2024, F. Hoffmann-La Roche Ltd., a Switzerland-based pharmaceutical company, announced U.S. Food and Drug Administration (FDA) approval for the VENTANA CLDN18 (43-14A) RxDx Assay, the first immunohistochemistry (IHC) companion diagnostic for assessing CLDN18 protein expression in gastric and gastroesophageal junction (GEJ) adenocarcinoma. This assay identifies patients eligible for targeted treatment with VYLOY (zolbetuximab) by measuring CLDN18 protein variants, primarily CLDN18.2. Utilizing the OptiView DAB IHC Detection Kit on the BenchMark ULTRA instrument, the test advances personalized healthcare, expanding treatment options for gastric and GEJ adenocarcinoma.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20797
What regions are contributing significantly to the growth of the gastric cancer market?
North America was the largest region in the gastric cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastric cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Gastric Cancer Drugs Global Market Report 2025
https://thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market-report
Gastric Cancer Drugs Global Market Report 2025
https://thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market
Gastric Volvulus Treatment Global Global Market Report 2025
https://thebusinessresearchcompany.com/report/gastric-volvulus-treatment-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on: